Patient-derived xenograft (PDX) models in basic and translational breast cancer research by Dobrolecki, Lacey E. et al.
Patient-derived Xenograft (PDX) Models In Basic and 
Translational Breast Cancer Research
Lacey E. Dobrolecki,
The Lester and Sue Smith Breast Center, Departments of Molecular and Cellular Biology and 
Radiology, Baylor College of Medicine, Houston TX 77030, dobrolec@bcm.edu
Susie D. Airhart,
The Jackson Laboratory, Bar Harbor, Maine 04609, Susie.Airhart@jax.org
Denis G. Alferez,
Breast Cancer Now Research Unit, Division of Molecular and Clinical Cancer Studies, 
Manchester Cancer Research Centre, University of Manchester, Wilmslow Road, Manchester, 
M21 4QL, UK, denis.alferez@manchester.au.uk
Samuel Aparicio,
Correspondence to: Michael T. Lewis.
*On behalf of the Breast Cancer Patient-derived Xenograft Consortium. Contributors appear in alphabetical order aside from the first 
and last authors.
Competing Financial Interests
Lacey E. Dobrolecki: Compensated part time employee of StemMed Ltd.
Susie D. Airhart: No competing financial interests
Denis G. Alferez: No competing financial interests
Samuel Aparicio: No competing financial interests
Fariba Behbod: No competing financial interests
Mohamed Bentires-Alj: No competing financial interests
Cathrin Brisken: No competing financial interests
Carol J. Bult: No competing financial interests
Robert B. Clarke: No competing financial interests
Matthew J. Ellis: Receives income from Washington University in St Louis which has licensed the WHIM series of breast PDX for 
commercial distribution
Eva Gonzalez Suarez: No competing financial interests
Richard Iggo: no competing financial interests.
Peter Kabos: No competing financial interests
Michael T. Lewis: Receives income from Baylor College of Medicine which has licensed the BCM series of breast PDX for 
commercial use. Founder and limited partner in StemMed Ltd., and a Manager in StemMed Holdings LLC.
Shunqiang Li: Receives income from Washington University in St Louis which has licensed the WHIM series of breast PDX for 
commercial distribution
Geoffrey J. Lindeman: No competing financial interests
Elisabetta.Marangoni: No competing financial interests
Funda Meric-Bernstam: No competing financial interests
Helen Piwnica-Worms: No competing financial interests
Marie-France Poupon: Founder and Scientific Advisor to Xentech SA, Genepole, 4 rue Pierre Fontaine, 91000 Evry, France
Jorge Reis-Filho: No competing financial interests
Carol Sartorius: No competing financial interests
Valentina Scabia: No competing financial interests
George Sflomos: No competing financial interests
François Vaillant: No competing financial interests
Jane Visvader: No competing financial interests
Alana Welm: Receives income if the University of Utah licenses the PDX models for commercial use
Max S. Wicha: No competing financial interests
HHS Public Access
Author manuscript
Cancer Metastasis Rev. Author manuscript; available in PMC 2017 December 01.
Published in final edited form as:













Dept. Path & Lab Medicine, BC Cancer Agency, 675 W10th Avenue, Vancouver V6R 3A6, 
Canada, saparicio@bccrc.ca
Fariba Behbod,
Department of Pathology, University of Kansas Medical Center, 3901 Rainbow Blvd, WHE 1005B, 
Kansas City, KS 66160, fbehbod@kumc.edu
Mohamed Bentires-Alj,
Department of Biomedicine, University of Basel, University Hospital Basel, Basel, Switzerland
Lab 306, Hebelstrasse 20, CH-4031 Basel, Switzerland, m.bentires-alj@unibas.ch
Cathrin Brisken,
ISREC - Swiss Institute for Experimental Cancer Research, School of Life Sciences, Ecole 
Polytechnique Fédérale de Lausanne (EPFL), SV2.832 Station 19, CH-1015 Lausanne, 
Switzerland. Phone +41 (0)21 693 07 81, Sec: +41 (0)21 693 07 62, Fax +41 (0)21 693 07 40, 
cathrin.brisken@epfl.ch
Carol J. Bult,
The Jackson Laboratory, Bar Harbor, Maine 04609, carol.bult@jax.org
Shirong Cai,
Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer 
Center, Houston, TX 77030, SCai1@mdanderson.org
Robert B. Clarke,
Breast Cancer Now Research Unit, Division of Molecular and Clinical Cancer Studies, 
Manchester Cancer Research Centre, University of Manchester, Wilmslow Road, Manchester, 
M21 4QL, UK, Robert.clarke@manchester.ac.uk
Heidi Dowst,
Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston TX 77030, dowst@bcm.edu
Matthew J. Ellis,
The Lester and Sue Smith Breast Center, Departments of Molecular and Cellular Biology and 
Radiology, Baylor College of Medicine, Houston TX 77030, Matthew.Ellis@bcm.edu
Eva Gonzalez-Suarez,
Cancer Epigenetics and Biology Program, PEBC, Bellvitge Institute for Biomedical Research, 
IDIBELL, Av.Gran Via de L'Hospitalet, 199 – 203, 08908 L'Hospitalet de Llobregat, Barcelona, 
Spain, egsuarez@idibell.cat, Phone: +34 932607347, Fax: +34 932607139
Richard D. Iggo,
INSERM U1218, Bergonié Cancer Institute, 229 cours de l'Argonne, 33076 Bordeaux, France, 
r.iggo@bordeaux.unicancer.fr
Peter Kabos,
Division of Medical Oncology, Department of Medicine, University of Colorado Anschutz Medical 
Campus, Aurora, CO 80045, Peter.Kabos@ucdenver.edu
Shunqiang Li,
Dobrolecki et al. Page 2













Department of Internal Medicine, Washington University, St. Louis, MO 63130, Tel. 314-747-9311, 
shunqiangli@wustl.edu
Geoffrey J. Lindeman,
Stem Cells and Cancer Division, The Walter and Eliza Hall Institute of Medical Research, 1G 
Royal Parade, Parkville, VIC 3052, Australia
Department of Medicine, The University of Melbourne, Parkville, VIC 3010, Australia
Familial Cancer Centre, The Royal Melbourne Hospital and Peter MacCallum Cancer Centre. 
Grattan St, Parkville, VIC 3050, Australia, lindeman@wehi.EDU.AU
Elisabetta Marangoni,
Translational Research Department, Institut Curie, 26, rue d’Ulm, 75005 Paris - FRANCE, 
Elisabetta.Marangoni@curie.fr
Aaron McCoy,
Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer 
Center, Houston, TX 77030, AMMcCoy@mdanderson.org
Funda Meric-Bernstam, MD,
Departments of Investigational Cancer Therapeutics and Breast Surgical Oncology, UT M. D. 
Anderson Cancer Center, Houston TX 77030, fmeric@mdanderson.org
Helen Piwnica-Worms,
Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer 
Center, Houston, TX 77030, hpiwnica-worms@mdanderson.org
Marie-France Poupon,
Founder and Scientific Advisor, Xentech SA, Genepole, 4 rue Pierre Fontaine, 91000 Evry, 
France, mariefrancepoupon@gmail.com
Jorge Reis-Filho,
Director of Experimental Pathology, Department of Pathology, Memorial Sloan Kettering Cancer 
Center, New York, NY
Affiliate Member, Human Oncology and Pathogenesis Program, and Center for Computational 
Biology, Memorial Sloan Kettering Cancer Center, New York, NY, reisfilj@mskcc.org
Carol A. Sartorius,
Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, 
Carol.Sartorius@ucdenver.edu
Valentina Scabia,
ISREC - Swiss Institute for Experimental Cancer Research, School of Life Sciences, Ecole 
Polytechnique Fédérale de Lausanne (EPFL), SV2.832 Station 19, CH-1015 Lausanne, 
Switzerland, valentina.scabia@epfl.ch
George Sflomos,
ISREC - Swiss Institute for Experimental Cancer Research, School of Life Sciences, Ecole 
Polytechnique Fédérale de Lausanne (EPFL), SV2.832 Station 19, CH-1015 Lausanne, 
Switzerland. georgios.sflomos@epfl.ch
Dobrolecki et al. Page 3














Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer 
Center, Houston, TX 77030, YTu1@mdanderson.org
François Vaillant,
Stem Cells and Cancer Division, The Walter and Eliza Hall Institute of Medical Research, 1G 
Royal Parade, Parkville, VIC 3052, Australia
Department of Medical Biology, The University of Melbourne, Parkville, VIC 3010, Australia, 
vaillant@wehi.edu.au
Jane E. Visvader,
Stem Cells and Cancer Division, The Walter and Eliza Hall Institute of Medical Research, 1G 
Royal Parade, Parkville, VIC 3052, Australia
Department of Medical Biology, The University of Melbourne, Parkville, VIC 3010, Australia, 
visvader@wehi.EDU.AU
Alana Welm,
Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope, Salt Lake City, UT 84112, 
Alana.Welm@hci.utah.edu
Max S. Wicha, and
Madeline and Sidney Forbes Professor of Oncology, Director, Forbes Institute for Cancer 
Discovery, NCRC 26-335S, SPC 2800, 2800 Plymouth Rd., Ann Arbor, MI 48109-2800, Phone: 
(734)763-1744, Fax: (734)764-1228, http://www.med.umich.edu/wicha-lab/index.html, 
mwicha@med.umich.edu
Michael T. Lewis*
The Lester and Sue Smith Breast Center, Departments of Molecular and Cellular Biology and 
Radiology, Baylor College of Medicine, Houston TX 77030, mtlewis@bcm.edu, TEL: 
713-798-3296, FAX: 713-798-1659
Abstract
Patient-derived xenograft (PDX) models of a growing spectrum of cancers are rapidly supplanting 
long-established traditional cell lines as preferred models for conducting basic and translational 
pre-clinical research. In breast cancer, to complement the now curated collection of approximately 
45 long-established human breast cancer cell lines, a newly formed consortium of academic 
laboratories, currently from Europe, Australia, and North America, herein summarizes data on 
over 500 stably transplantable PDX models representing all three clinical subtypes of breast 
cancer (ER+, HER2+, and “Triple-negative” (TNBC)). Many of these models are well-
characterized with respect to genomic, transcriptomic, and proteomic features, metastatic behavior, 
and treatment response to a variety of standard-of-care and experimental therapeutics. These stably 
transplantable PDX lines are generally available for dissemination to laboratories conducting 
translational research, and contact information for each collection is provided. This review 
summarizes current experiences related to PDX generation across participating groups, efforts to 
develop data standards for annotation and dissemination of patient clinical information that does 
not compromise patient privacy, efforts to develop complementary data standards for annotation of 
PDX characteristics and biology, and progress toward “credentialing” of PDX models as 
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surrogates to represent individual patients for use in pre-clinical and co-clinical translational 
research. In addition, this review highlights important unresolved questions, as well as current 
limitations, that have hampered more efficient generation of PDX lines and more rapid adoption of 
PDX use in translational breast cancer research.
Keywords
Patient-derived xenograft; breast cancer; immunocompromised/immunodeficient mice; 
translational research; PDX consortium
I. Introduction
Human breast cancer is now recognized, not as a single disease, but as a heterogeneous 
collection of diseases characterized by diversity in histology, genomic alterations, gene 
expression, metastatic behavior, and treatment responses [1–7]. In addition to heterogeneity 
between tumors across the patient population (or between two primary tumors in a single 
patient), recent data have also demonstrated considerable intra-tumoral heterogeneity (that is 
between cells within a single tumor, and between a primary tumor and its associated 
metastases in a single patient). This degree of heterogeneity is a significant hindrance for 
making effective treatment decisions, and begs for the development of personalized 
approaches to therapy based on the specific biology of an individual, and their unique tumor 
[8]. With respect to basic and translational research, the existence of disease heterogeneity, 
both within and among breast cancers, also presents significant challenges to generation and 
use of relevant pre-clinical models that represent the full spectrum of breast disease [9,10].
If our ultimate goal is to offer each breast cancer patient an individualized treatment plan 
tailored to her (or his) specific tumor and progression status, it will be essential to define 
fully the molecular and cellular heterogeneity within and among the tumor subtypes, and 
indeed within each patient’s tumor, and relate these differences to clinical behavior. 
Specifically, these characteristics need to be linked to metastatic behavior and differential 
treatment response, the lethal aspects of breast cancer, in order to ‘personalize’ effective 
treatment. Patient-derived xenograft (PDX) models hold high promise as a discovery and 
validation platform, particularly as a unified collection across multiple institutions, for 
meeting this daunting challenge.
I.A. The Problem of Inter-tumoral Heterogeneity
Clinically, breast cancers are divided essentially into three subtypes: 1) those that express the 
estrogen receptor alpha (ER+) (which typically also express the progesterone receptor (PR
+)), 2) those that are genomically amplified for and/or overexpress ERBB2 (HER2+) 
(encoding a member of the epidermal growth factor receptor family of tyrosine kinases), and 
3) those that express none of these three markers (termed “triple negative” breast cancer 
(TNBC)) [1–4]. While clinically useful, molecularly targeted therapies exist for ER+ breast 
cancer (e.g. Selective Estrogen Receptor Modulators (SERMs), aromatase inhibitors (AI), 
Selective Estrogen Receptor Downregulators (SERDs)) [11] and HER2+ breast cancer (e.g. 
Trastuzumab, Lapatinib) [12], there are currently no approved targeted therapies for TNBC. 
Dobrolecki et al. Page 5













Current treatment of TNBC entails surgery coupled with radio- and/or chemotherapy (most 
often taxane- or anthracycline-based, with platinum-based agents emerging as promising 
first line therapies (e.g. [13])) in either the neoadjuvant (before surgery) or adjuvant (after 
surgery) settings.
With the development of RNA expression array technology over 15 years ago, more detailed 
molecular classification of breast cancer became possible. In a landmark analysis of global 
RNA expression, five intrinsic molecular subtypes of breast cancer were proposed: luminal 
A (ER+, with signatures consistent with lower proliferation rates that can be correlated with 
comparatively lower Ki67 immunostaining), luminal B (ER+, with signatures consistent 
with elevated proliferation that can be correlated with comparatively higher Ki67 
immunostaining), basal-like (predominantly TNBC), HER2-enriched, and normal breast-
like. Each molecular subtype correlated with unique clinical behavior including differences 
in overall survival, patterns of metastasis, and response to treatment [5,4,7,6]. Subsequently, 
the claudin-low subtype was identified. Claudin-low tumors are predominantly TNBC, with 
comparatively low expression of Claudins 3, 4, and 7 [14], enrichment for mesenchymal 
markers [5], and enrichment of a stem cell-like (CD44+/CD24Neg/Low) gene expression 
signature [15,5,16].
Within the last 5 years, detailed genomic analysis of breast cancers by several groups 
including the ICGC, TCGA and METABRIC consortia [17–21], have shown that additional 
molecular subytypes associated with distinct survival trends can be distinguished, such as 
the 4% of breast cancers that are ER+ with complex amplifications around 11q [18] and 
those showing differential survival associated with PIK3CA mutation [22,23]. TNBC has 
been found to constitute at least two and perhaps more, distinct biological subgroups based 
on integrated genomics [24] – a genomically quiescent, PIK3CA mutation-containing, 
intermediate-good prognosis group (about 25% of TNBC), that group more with ER+ 
cancers (a proportion express AR) of the IntClust4 subtype and the remainder which are 
almost universally mutated for TP53, have unstable genomes, a basal epithelial gene 
expression signature type and poor prognosis with early relapse. Some TNBC gene 
expression studies have suggested TNBC could be subdivided further into four or more 
distinct subgroups [25–28]
I.B. The Problem of Intra-tumoral Heterogeneity
Pathologists have long appreciated heterogeneity in both histology and biomarker expression 
within a given tumor. For example, in ER+ tumors, not all cells express the receptor. 
Clinically, ER+ breast cancers can be qualified as such even if only 1% of cells express 
detectable levels of ER protein, though some low-expressing tumors may behave as ER-
negative tumors in response to targeted therapies [29,30]. Similarly, HER2+ tumors can 
show regional variation in expression by immunohistochemistry and copy number per cell 
by fluorescence in situ hybridization, with positivity clinically defined as 10% of cells 
positive (CAP Guidelines) [31,32,12].
Although clonal structure has been appreciated as a defining feature of cancers for several 
decades [33], methods for understanding clonal structure in solid epithelial cancers have 
only recently advanced. Until very recently, the existence of genetically distinct 
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subpopulations within tumors, and within metastatic cell populations, was not appreciated 
(see [34–36] and references therein). With the development of computational approaches to 
infer clonal structure from bulk tumor sequence data (eg. [37–40,20,41]), as well as methods 
for single cell DNA and RNA sequencing (eg [42–48]), breast cancers are now known to 
contain multiple genetically distinct subclones [49,50]. Primary TNBC have been shown to 
be clonally diverse among patients with the same stage/grade of tumour. Further work 
suggests that distinct subclones may, in some instances, be capable of interacting with one 
another to maintain homeostatic balance between clonal populations, and promote tumor 
growth [51].
I.C. Patient-derived breast cancer xenografts as potentially powerful tools for pre-clinical 
and translational research
In theory, if PDX models can represent the full spectrum of heterogeneity of breast cancers 
in the population, and can be fully “credentialed” to retain the critical molecular and 
biological properties of their tumor of origin, these models would then represent 
exceptionally powerful tools for translational research. In large part, their potential power 
lies in the fact that they have been demonstrated to be biologically stable (generally) and, as 
such, are renewable indefinitely. Thus, PDX models can be interrogated in greater depth 
both biologically and molecularly than any given patient sample is likely to be (unless very 
large). Further, PDX can be challenged with as many candidate therapeutics, or treatment 
regimens, as desired in a relatively short time frame versus what can be accomplished in the 
clinic. In contrast, the tumor of origin (and patient), can only be challenged sequentially with 
one treatment regimen at a time, and only at significant risk of potentially lethal or 
debilitating side effects.
Herein, we garner the collective experience of a new international consortium of breast 
cancer PDX developers to review the state-of-the-art in the field, to outline open questions 
remaining to be addressed, and to summarize the utility, limitations, and future promise of 
breast cancer PDX models in translational research.
II. The State-Of-The-Art In Breast Cancer PDX Modeling
II.A. Patient-derived xenografts (PDX) models that represent all three clinically-defined 
breast cancer subtypes have been established by various groups
In addition to the need to represent the heterogeneity of breast cancers as completely and 
accurately as possible, breast cancer is heavily influenced by the tumor microenvironment, 
making in vivo models desirable for studying complex processes like tumor metastasis and 
response to therapy. Efforts to establish stably transplantable xenograft lines directly from 
patients into immunocompromised mice have been going on for decades. Unfortunately, 
while initial take rates (i.e. initial outgrowths directly from patients) can be quite high (~40–
90%) [52–54], success rates of generating stably transplantable xenografts (generally, but 
not uniformly, defined as PDX with the ability to be serially transplanted ≥3 passages in 
mice (variously termed “passage 2 (P2)”, with P0 being the initial transplant from mouse to 
human, or “transplant generation 3 (TG3)”) (Tables 1 and 3) from early efforts were 
comparatively low, in the 10% range overall [52,55–64,53]. As a consequence, few stably 
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transplantable models were established for dissemination to the research community from 
this earlier work.
More recently, with newly-developed immunodeficient host mouse models [65], and 
modified transplantation conditions, overall stable take rates have now reached in excess of 
20% on a routine basis (e.g. [66,54,67–73,37,74,75,13]). Further, a concerted effort is being 
made to develop these collections of stable, well-characterized, PDX lines as quality-
controlled, renewable tissue resources for distribution to the research community. A list of 
PDX collections available for dissemination, along with the patient/tumor population 
characteristics from which they were derived, is presented in Table 1; contact information 
for each collection is listed in Table 2. In addition to collections resident in academic 
institutions, several commercial entities retain PDX collections of their own, consisting of 
PDX lines either generated in house, or licensed from academic institutions. These 
commercial collections are not discussed here.
Taken in aggregate, the academic institutions participating in this consortium have developed 
537 individual PDX lines, representing over 500 unique patients. With respect to clinical 
subtypes represented, 56% of patients yielding PDX lines had TNBC, with 36% of patients 
having ER+ cancer. Patients with HER2+ breast cancer are significantly underrepresented in 
these collections, representing only 8% of patients yielding PDX models, due to the 
combined facts that they represent only ~10–15% of all breast cancers, and show a lower 
overall take rate than TNBC (which also accounts for 10–15% of all breast cancers, but 
show a higher take rate) (Table 3).
Given the clinical observation that patients of different ethnic and racial backgrounds can 
have distinct treatment responses and disease outcomes, an important consideration is the 
ethnic and racial distribution of patients yielding PDX lines. In general, the diversity of PDX 
lines in a given collection represents the diversity in the associated patient population from 
which they were derived. While Caucasian women are most heavily represented across these 
collections, there are now a number of PDX lines representing African American and 
Hispanic women (Table 1). However, only a few PDX lines represent patients of Asian or 
African descent, and no PDX lines represent indigenous populations (e.g. Native 
Americans), or male breast cancer patients, among others.
Of note, the PDX lines representing Continental African patients from Ghana (Wicha et al, 
unpublished) were developed using primary tumor samples that had been viably frozen and 
shipped on dry ice prior to transplantation using a recently tested cryopreservation strategy 
(Table 3) (Lewis et al, unpublished), thus demonstrating that it should be possible to develop 
PDX tissue resources representing patients even from remote and underserved areas in the 
world where no active PDX development efforts may exist.
Finally, it is critical to recognize that the collections included in this review are exclusively 
from academic groups in Europe, Australia, and North America. Going forward, it will be 
important to include additional collections from other geographic regions that undoubtedly 
will have better representation of the patient demographics of the regions in which they 
function. Researchers and clinicians interested in participating in this International Breast 
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Cancer Patient-derived Xenograft Consortium should contact the corresponding author 
(M.T. Lewis) to be added to the mailing list.
III. Open Questions Regarding Generation and Use of Breast PDX Models
Detailed protocols currently used for generation of patient-derived xenograft (PDX) models 
breast cancer have been published recently by De Rose et al and Zhang et al. [54,72], and 
will not be discussed in detail here. Similarly, the advantages and limitations of PDX models 
relative to clinical samples and established cell lines have also been discussed in detail 
elsewhere [76–79]. For the purposes of this review, we will briefly restate and highlight 
some of these strengths and limitations, but in the context of particular unresolved questions 
and issues currently being addressed by the breast PDX community.
III.A. Are PDX really any better than xenografts made using long-established cell lines?
A number of immortalized or transformed cell lines have been established and extensively 
characterized over the last several decades, notably the MCF series, the MDA series, and 
more recently the SUM series (see [80–82] and references therein). Extensive efforts have 
been made to correlate gene expression, genomic copy number changes, and mutations with 
growth characteristics and therapeutic responses [83–86]. Unfortunately, while all of these 
cell lines grow in vitro under tissue culture conditions, only a percentage of these will grow 
when transplanted as cell line xenografts, and a fewer will form metastases despite many of 
them being derived from pleural effusions and ascites [87–91]. Thus, a large proportion of 
the studies aimed at translational endpoints using cell lines have been conducted in vitro, 
rather than in vivo as cell line xenografts.
It is now appreciated that gene expression patterns under 2-dimensional in vitro culture 
conditions can be quite different than expression patterns observed under 3-dimensional 
culture conditions, or when cell lines are grown as xenografts in immunocompromised mice 
[92]. Similarly, drug sensitivity under varied conditions can be different for a given cell line 
[93]. Indeed, in transcriptome studies of clinical samples versus established cancer cell lines, 
cell lines clustered together regardless of the tissue of origin, rather than clustering with the 
clinical samples they were intended to model [94]. Given these differences, it is perhaps to 
be expected that cell line based studies have failed to translate clinically with high 
frequency, and thus may not be suitable to address many clinical questions [95,8]. In 
contrast, PDX lines are, by their nature, established and maintained in vivo, and have been 
shown to retain a remarkable degree of biological, histological, genomic, transcriptomic, and 
biomarker fidelity with their tumors of origin (see below).
Most established human breast cancer cell lines have been maintained in vitro over several 
decades, and in many different laboratories. Long-term culture has, in several cases, been 
associated with extensive clonal selection, and loss of heterogeneity [94,96]. Further, 
inconsistent handling, as well as both inadvertent and deliberate selection, are known to have 
led to genetic drift such that a multitude of sub-lines of individual parental lines now exist. 
As such, isolates of a given cell line (e.g. MCF7) can vary considerably from laboratory to 
laboratory with respect to genomics and gene expression [97,98]. Each sub-line can thus 
possess its own unique attributes (invasive vs. not, metastatic vs. not, adherent vs. not, drug 
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resistant vs. sensitive, etc.). Further, since the tumor of origin from which a given cell line 
was derived cannot be studied in most cases, and only limited clinically-relevant data were 
collected, there is typically no way to evaluate what the original mutation spectrum in the 
patient was, or what the clinical behavior of the tumor of origin actually were. Taken 
together, these shortcomings limit the utility of established breast cancer cell lines for 
predictive/correlative studies. However, these shortcomings do not necessarily impinge on 
the use of established cell lines to investigate basic biological mechanisms. In contrast, PDX 
show behavioral, genomic, transcriptomic, and proteomic stability over at least 15 transplant 
generations in mice [54]. These attributes can be quality controlled from inception of the 
model, and in many cases, this can be done with direct comparison with the clinically 
annotated tumor of origin.
Finally, unlike the vast majority of long-established human breast cancer cell lines, a 
majority of PDX lines were established from primary tumors rather than tumor cells derived 
from pleural effusions, ascites, or other metastatic sites. Thus, in perhaps an important way, 
PDX lines may serve to complement existing cell lines rather than supplant them, depending 
on the question(s) being asked.
III.B. To what degree do PDX models truly recapitulate the biology of the tumor of origin in 
the patient, particularly with respect to treatment response?
One of the main open questions relates to whether PDX models retain the intra-tumoral 
heterogeneity of the tumor of origin. While many PDXs appear to retain the heterogeneity of 
the parental tumor of origin, loss of heterogeneity, or a “bottlenecking” clonal selection upon 
transplantation, has been observed in others [44]. An example of such selection came from 
comparative genomic sequence analysis of a primary tumor, a patient matched brain 
metastasis, and a PDX model derived from the primary tumor [37]. As expected, the 
metastatic lesion retained mutations found in the primary tumor, but also possessed de novo 
mutations and deletions not observed in the primary tumor. Also as expected, the PDX 
derived from the primary tumor retained the primary tumor mutations. Unexpectedly, the 
PDX showed the mutation spectrum found in the metastasis indicating that the metastatic 
subclone was present within the primary tumor, and that it was this aggressive subclone that 
grew as a PDX. Thus, it is critical to compare the tumor of origin with its related PDX line 
as carefully as possible, whenever possible, to ensure accurate recapitulation of as much 
patient/tumor biology as possible, including tumor heterogeneity.
As recounted above, the inability to relate a cell line to its patient of origin is one of the 
primary places where long-established cell lines fall short. Thus, cell lines simply cannot be 
used for this purpose. In contrast, PDX models, and the tumors from which they were 
derived, have been compared directly at multiple levels in several studies. At the histological 
level, several studies have demonstrated that PDX are virtually indistinguishable from the 
tumor of origin, including H&E stained sections, as well as by immunostaining for 
biomarkers such as ER, PR, HER2, and Ki67 positivity etc. At the genomic level, PDX show 
similar genomic rearrangements, copy number alterations, mutation profiles, and variant 
allele frequencies [99,71–73,100], observed in the tumor of origin. These results 
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demonstrate not only stability of the PDX when transplanted from one species to another, 
but also transplantability of clonal heterogeneity in many cases.
At the transcriptome level, PDXs generally show remarkable fidelity with respect to mRNA 
expression profiles (RNAseq) [101,73]. While proteomic comparisons between PDXs and 
their respective tumors of origin have not yet been completed, as stated previously, both 
transcriptomic and proteomic (RPPA) expression patterns have been shown to be remarkably 
stable across transplantation generations [54].
With respect to metastatic behavior, this is an open and active area of investigation across 
several groups. In general, PDX have been shown to produce circulating tumor cells, as well 
as disseminated micro and macro metastases to several distant sites ([71,102,54,103] and 
Miragaya et al, unpublished). When evaluated for fidelity with the metastatic behavior of the 
tumor of origin, PDX showed comparable metastatic site specificity ([71] and Miragaya et 
al, unpublished). As expected, PDX models are generally more metastatic in more 
immunocompromised hosts (e.g. larger metastatic nodules in NSG mice versus NOD/SCID; 
ALW unpublished data). This could be due to faster tumor growth and/or more permissive 
colonization of the distant sites. These observations warrant further investigation to test the 
generality of these initial findings, and to test the degree of influence of the immune system 
in the metastatic process.
III.C. What is the status of Patient-PDX “credentialing” for relevance of PDX models in 
therapeutic studies?
Among the most critical issues to be addressed is whether PDX models respond to a given 
treatment in a manner similar to the tumor of origin in the patient. If so, PDX models should 
serve not only as relevant as experimental models, but also as valuable translational research 
tools, especially if ultimately shown to have predictive value clinically. Again, this is a very 
active area of investigation in several groups. However, no “treatment standards” are yet 
available, largely due to the lack of comparative pharmacokinetic and pharmacodynamics 
data that would allow researchers to translate directly between PDX evaluation and clinical 
evaluation.
In preclinical treatment studies conducted to date, PDX showed comparable responses to the 
tumor in the patient of origin when treated with comparable therapeutic agents. An early 
study evaluating 7 xenografts showed an observed concordance of response between patient 
tumor and corresponding PDX of 71% vs. a statistically expected concordance of 47% [68]. 
However, sample size was limited for direct comparison due to the types of treatments used 
clinically (adjuvant or post-radiation chemotherapy) in this patient cohort that could not 
easily be recapitulated in mice, thus statistical significance was not quite reached using this 
sample size (Kappa=0.46, p=0.08). In a later study, a majority of xenograft lines tested also 
showed qualitatively identical treatment responses as the corresponding patient treated with 
a similar or identical agent in the neoadjuvant (before surgery) setting, and statistical 
significance was achieved using this increased sample size [54]. Overall concordance of 
responses was ~92% (Ƙ = 0.75, P = 0.003), and there was a significant association between 
the xenograft and patient-derived results (Fisher exact test, P = 0.04). While both studies 
were relatively small, taken together, PDX do recapitulate tumor responses seen clinically 
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with good efficiency. Importantly, at least with respect to these selected Standard of Care 
agents, and under the specific conditions tested, this recapitulation does not appear to be 
influenced by the immunodeficiency of the host mice used. Thus, PDX models and 
associated data should serve as useful predictors of response in patients with at least some 
agents under some conditions. However, this hypothesis remains to be tested in a rigorous 
manner in both retrospective and prospective (co-)clinical trials.
III.D. Which immunocompromised mouse model should be used for most efficient PDX 
generation while still retaining the highest possible fidelity with the human disease?
A variety of immunocompromised, or immunodeficient, mouse models now exist that can be 
used as transplantation hosts to develop breast cancer PDX models (Table 3). While all 
mouse models listed are capable of generating PDX models under various transplant 
conditions, and using various sample types, a consensus has yet to be reached as to the 
“best” host to use. Thus, choice of immunocompromised host remains largely a question of 
investigator preference until rigorous head-to-head studies are conducted, and a large enough 
body of data is available for multivariate analysis. Such data need to be related not only to 
the various transplantation conditions being employed, but also to the characteristics of the 
underlying patient populations, and tumor types, being evaluated in order for meaningful 
conclusions to be drawn.
III.D.1. Athymic nude mice—Until approximately a decade ago, the most commonly 
used immunocompromised mouse model used for generation of breast cancer xenografts 
was the athymic “nude” mouse [104–106], which is homozygous for loss-of-function 
mutation of the Foxn1 gene (encoding the Forkhead box N1 transcription factor) (a.k.a. nu, 
Hfh11) [107,108]. The Foxn1 gene is essential for the development of the thymus and some 
ectodermal derivatives, including hair follicles (hence the “nude” phenotype), and leads to 
loss of functional T- and B-cells. The mice retain functional natural killer (NK) cells, 
macrophages, and antigen presenting cells (APC).
To support growth of estrogen-dependent breast cancer cell lines, athymic mice require 
supplementation with estradiol due to low endogenous levels of circulating estrogen [109–
112]. The same appears to be true for other immunocompromised mice - even if they may 
have higher estrogen levels, cell lines only grow when the mice are supplemented with 
exogenous estradiol. While historical rates of generating stable PDX lines have been 
relatively low using nude mice, alternative transplantation methods (e.g. subcutaneous 
transplantation of tumor fragments into the intra-scapular fat pad or flank), does appear to 
allow efficient PDX establishment (Table 3) ([68,113,114], Gomez-Miragaya et al, 
unpublished).
III.D.2. Rag1/Rag2 mice—Rag recombinase-deficient (Rag1 and/or Rag2) mice have 
been used sporadically for xenograft studies, mainly for generating cell line xenografts. 
However, these mice have not been used extensively for attempts to generate PDX lines (see 
Table 3). Like athymic nude mice, B- and T-cell function is abrogated [115] due to loss-of-
function of the recombinases required for the somatic recombination of antibody chains and 
mature T-cell receptors. Rag knockout mice may be a useful alternative for some treatment 
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response studies using anthracycline-based or other DNA damaging therapies because the 
consequences of Rag mutations are relatively specific to the hematopoietic system. As such, 
these mice can tolerate higher levels of DNA damage than mice carrying the SCID mutation 
(Prkdc, which encodes a ubiquitious DNA repair enzyme, see below) [116].
III.D.3. SCID mice—Most of the major breakthroughs made in efficient generation of PDX 
lines have been made using newer, more immunocompromised, mouse models. These 
include SCID (severe combined immunodeficiency disorder) mice which carry a mutation of 
the Prkdc gene (protein kinase, DNA activated, catalytic polypeptide) encoding a protein 
kinase required for somatic VDJ (variable, diversity, joining) region recombination of 
antibody chains and T-cell receptors, as well as for DNA repair. Such mice show B- and T-
cell deficiency, but background-dependent leakiness does occur. SCID mice retain cellular 
immunity [117–121]. The SCID mutation is generally used in combination with other 
mutations that further cripple the immune system for xenograft work. However, SCID mice 
remain prone to premature death, due in part to their high prevalence of spontaneous T-cell 
lymphomas [121].
III.D.4. SCID/Beige mice—Combination of the Beige (Bg) mutation with the SCID 
mutation has been shown to enhance the take rate of human leukemias and other cell types, 
including breast cancers [122–125,54]. In addition to B- and T-cell deficiencies, disruption 
of Bg results in a lysosomal trafficking defect and eliminates NK cell function, but leads to a 
~3-fold increase in the number of macrophages relative to the parental wild type Balb/C 
mice [126,127,122,123]. Macrophages are essential for normal mammary gland 
development. As such, this increase in macrophage content may be advantageous [128,129]. 
Further, recent data showing promotion of tumor invasion and metastasis by immature 
myeloid cells of the macrophage lineage may account for some of the advantages of this 
immunocompromised background [130]. Use of this genetic background allows stable take 
rates in excess of 20% under various conditions, but successful transplantation in this 
background is enhanced significantly by estradiol supplementation (Table 3) [54], likely by 
an ER-alpha-mediated stimulation of bone marrow-derived monocytes [54,131].
III.D.5. NOD/SCID mice—A major advance for the generation of PDX models came after 
genetic introgression of the NOD (non-obese diabetic) mutation in to the SCID background, 
which compromises cellular immunity, via impaired function of NK, APC and macrophage 
cells. While impaired, presence of NK and macrophages in athymic and NOD/SCID mice 
can lead to elimination of tumor cells over time [132–134]. Use of this background has 
allowed take rates in excess of 20% on a routine basis (Table 3) (see [71,135,69,136] and 
Gomez-Miragaya et al., unpublished; Piwnica-Worms et al., unpublished).
III.D.6. NOG and NSG Mice—Development of the NOD/SCID background has continued 
with the addition of IL2-receptor gamma truncation/disruption mutations (“NOG” or “NSG” 
mice, respectively) which compromises the mouse immune system further by impairing 
cytokine signaling involved in innate cellular immunity [65,137,138]. Use of this 
background has been extensive across multiple groups, and has allowed take rates in excess 
of 20% overall to be achieved on a routine basis (Table 3) 
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([69,71,54,37,139,74,140,73,141]} and Gonzales-Suarez et al., unpublished; Bult et al. 
unpublished). The primary distinction of the NSG and NOG strains is that the function Il2rg 
in NSG is completely ablated. In NOG, the Il2rg mutation still produces a protein product 
that can bind to cytokines, but there is no signaling activation. NSG mice are less susceptible 
to thymic lymphomas than NOD/SCID mice, and have a longer lifespan, making them well-
suited for engrafting slower growing human tumors.
An interesting modification of the NSG is the NRG strain, which replaces the SCID 
mutation with a Rag1 mutation. These mice were used recently for the intraductal injection 
approach for PDX development [141]. Evaluation of NRG mice in experimental therapeutic 
studies involving DNA-damaging agents would be of considerable interest.
The NSG recipient mouse has been shown to support greater engraftment of human 
hematopoietic stem cells (hu-CD34+ cells) than some other currently available strains 
[137,142]. As a consequence NSG mice can be engrafted with functional human immune 
systems permitting the potential to study primary human tumors in vivo in the presence of a 
human immune system. However, NSG mice are also reported to develop lymphocytic 
neoplasms occasionally from human B- and T-cells co-transplanted with the human tumor 
fragments, which rapidly outgrow human epithelial tumor cells [143,144]. Nonetheless, 
NSG mice are currently the most popular choice for developing breast cancer PDX, with the 
majority of the consortium groups using NSG exclusively or in combination with other 
strains.
III.D.7. Comparisons of immunocompromised hosts with regard to breast 
cancer PDX modeling—With multiple host mouse models capable of generating PDX 
lines under a variety of conditions, using a broad range of tumor types, it is important to note 
that controlled head-to-head comparisons of single tumor fragments transplanted into 
multiple immunocompromised host models under otherwise identical transplant conditions 
have not been conducted extensively. Thus, it is not currently possible to state definitively 
that one immunocompromised mouse model is superior to any other for generating breast 
PDXs. Similarly, comparison of take rates achieved between various groups is difficult due 
to considerable differences in tumor types used for transplantation (e.g. low grade vs high 
grade primary cancers, primary tumors vs. metastatic tumors, before or after treatment) and 
patient cohort characteristics (e.g. ethnically diverse or not).
Limited side-by-side comparisons of engraftment efficiency have been performed suggesting 
the SCID/Bg or NOG/NSG backgrounds may provide superior engraftment of various types 
of human cells [122–125]. Indeed, when comparing two similar cohorts of breast cancer 
patients, primary tumors showed equivalent take rates in either the SCID/Bg or NSG 
backgrounds [54]. However, this study was not a head-to-head comparison using exactly the 
same patient sample into both backgrounds simultaneously. While the range of PDX models 
produced in these two backgrounds was similar, it remains possible that each genetic 
background might favor the establishment of different types.
Some studies have now shown that positive engraftment of breast tumors into certain mouse 
strains correlates with high tumor grade or poor patient outcome [145,71,66,99] Whether the 
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prognostic value of engraftment would extend to more immunocompromised hosts, or 
whether retention of some cellular immunity in the host provides more information 
regarding tumor aggressiveness in the patient is still unknown.
III.E. What is the best transplantation site?
A variety of transplantation sites are available in the mouse, and several have been used in 
attempts to generate breast cancer PDX models. Tissue can be transplanted into the anterior 
compartment of the eye [146,147], under the renal capsule [148–151], within the 
intrascapular fat pad [68], subcutaneously (ear, flank, etc.), orthotopically within the 
mammary fat pad (either the intact (IFP), or epithelium—free “cleared” (CFP) fat pad) [152] 
or injected into the mammary ducts themselves [153,154,141].
In addition to these approaches for modeling primary tumors"experimental metastasis” 
methods have been developed in which tumor cells are injected through the tail vein, the 
iliac artery, or by intracardiac injection, allowing establishment of tumors at other organ sites 
including bone, brain, lung, and liver (e.g. [155–160] and references therein). A bone-to-
bone xenograft experimental metastasis model has also been developed [161].
With respect to PDX model development, subcutaneous and orthotopic transplantation sites 
are generally used (Table 3), with orthotopic transplantation into the mammary fat pad 
considered preferable by some as it should more closely represent the human breast with 
respect to the microenvironment. However, the intraductal approach is also attractive with 
respect to the range of orthotopic options available. For example, in one study, cells from 16 
tumours that successfully formed primary grafts after intraductal injection failed to engraft 
at 26 subcutaneous injection sites [141], but direct comparison of intraductal with 
sophisticated extraductal grafting techniques has not been performed.
III.F. Is it necessary to eliminate endogenous mouse epithelium from the mammary fat pad 
(i.e. “clear” the fat pad) for efficient orthotopic transplantation?
Elegant transplantation studies conducted nearly six decades ago [162,152,163] 
demonstrated that the adult mammary gland contains growth-quiescent epithelial 
regenerative stem cells that are distributed throughout the entire gland. These stem cells 
could be activated to self-renew upon transplantation of small duct fragments (~1000–2000 
cells) into the epithelium-free mammary fat pad of recipient mice, and were capable of 
regenerating a morphologically normal and functional, ductal tree. However, these same 
fragments would not regenerate a ductal tree in the presence of pre-existing ducts in the 
recipient animal. Thus, the presence of endogenous normal epithelium is inhibitory to 
transplanted epithelium, thereby necessitating removal of the endogenous epithelium 
(“clearing”) for the transplant to grow.
In contrast, neoplastic tissue transplanted into an intact fat pad will grow in the presence of 
endogenous normal epithelium. However, this ability does not necessarily mean that 
inhibitory signals do not exist, only that neoplastic tissue is capable of overcoming them, or 
is unresponsive to them, should they exist. Thus, while neoplastic tissue may be able to 
overgrow normal epithelium, removal of whatever inhibitory influences may exist might 
allow neoplastic tissue to grow even better. Conversely, it is formally possible that normal 
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epithelium could promote growth of neoplastic tissue. These alternative hypotheses have not 
been tested in a controlled manner.
From inspection of Table 3, use of the intact mammary fat pad (IFP) does not appear to 
interfere with effective transplantation of primary tumor tissue. In fact, there are preliminary 
indications that the IFP may be superior to the CFP for transplantation of both fresh, and 
previously cryopreserved, tumor tissue (Table 3). That said, the continued presence of 
endogenous mouse epithelium may complicate some downstream molecular analyses (e.g. 
transcriptome arrays, Reverse Phase Protein Arrays (RPPA) etc.), and so use of the IFP may 
not be desirable in all instances.
III.G. Is estradiol supplementation necessary? If so, what is the most effective way to 
deliver it?
With the possible exception of metastatic ER+ breast cancer, it has proven difficult to 
establish PDX models of primary, particularly lower grade, ER+ luminal A tumors. Further, 
once established ER expression can be lost over the course of passaging from mouse to 
mouse (e.g. [68,57,164], Miragaya et al. unpublished), though many current studies have not 
shown this behavior. These difficulties are offset, in part, by the fact that ER+ cancers 
account for approximately 75% of all breast cancers, thus offering more opportunities to 
make successful PDX models.
In attempts to increase the take rate of ER+ tumors, various forms of estradiol 
supplementation have been used, ranging from commercially prepared slow-release plastic 
pellets (e.g. Innovative Research), to hormone-loaded silastic tubes, or bee’s wax pellets. To 
date, progesterone supplementation, either alone or in combination with estradiol, has not 
been evaluated. Unfortunately, in addition to significant urinary tract complications 
associated with the use of estradiol-containing implants of all sorts, the major issue with this 
approach is that the implant becomes depleted of hormone over time, requiring periodic 
replacement if hormone levels are to be maintained long-term. To address these issues, 
several groups have revisited use of an old method by testing the ability of estradiol-
supplemented drinking water for its ability to support PDX growth with promising results 
(Table 3) (see [68,165–168,136] Lewis et al., unpublished). Given the significant limitations 
of delivery using implants, estradiol-supplemented drinking water may be a superior method 
of delivery. However, it remains unclear whether rates of PDX establishment will be 
comparable to those using other delivery methods.
While most groups engaged in PDX generation use some form of estradiol supplementation 
for ER+ tumors, use of supplementation is not always used when transplanting ER- tumors 
(Table 3) [71,114,113] - the reasoning for not using supplementation being that ER- tumors 
should not require estradiol supplementation for their growth. However, comparison of 
stable take rates of primary cancers from statistically similar cohorts in the SCID/Bg host 
strain, with and without supplementation with slow-release estradiol pellets, demonstrated 
that supplementation increased the stable take rate almost 10-fold, from 2.6% without 
supplementation (only a single TNBC PDX generated from 38 patients attempted) to 21% 
with supplementation (15 PDX representing multiple IHC subtypes from 70 patients 
attempted) in this host background [54]. These data indicating a requirement for estradiol 
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supplementation were consistent with previous studies showing that estradiol 
supplementation stimulates growth of breast cancer xenografts, including ER-negative 
xenografts [71,169,170,69]. Subsequently, the stimulatory effect of estradiol 
supplementation on ER-negative tumor was investigated specifically and shown to be due, in 
part, to an effect on bone marrow-derived myeloid cells that promote angiogenesis and 
tumor growth that was dependent on ERα [131,171].
Of potential significance, several groups have successfully used NSG mice without estradiol 
supplementation (Table 3), suggesting that unlike SCID/Bg, successful transplantation in 
NSG animals may not require supplementation. However, there may be significant 
differences in the patient cohorts and tumor characteristics from one group to another that 
may contribute to this apparent difference. That said, the intraductal approach appears to 
also one to grow ER+ cell lines and PDX in the absence of endogenous hormones [154,141].
It will be critical to address these potential host background differences going forward.
III.H. How can lower grade tumors, ductal carcinoma in situ (DCIS), and normal tissue be 
grown with higher efficiency?
While it has been comparatively easy to establish PDX models from metastatic sources such 
as ascites and pleural fluid, as well as from high grade, more aggressive primary tumors 
from the breast itself (Table 3), it has proven relatively difficult to establish PDX from grade 
I/II tumors, DCIS, and normal breast epithelium [153,75,54,66,70,114,113].
One possible explanation for elevated take rates in high grade primary tumors could be a 
higher frequency of tumor-initiating cells (TIC) (a.k.a. cancer stem cells) relative to lower 
grade tumors [172,173]. In one study, the frequency of cells expressing ALDH1 (aldehyde 
dehydrogenase 1), a marker associated with TIC properties in some, but not all, breast 
cancers, predicted the rate of engraftment as a PDX. The general hypothesis is that the 
higher the proportion of TIC, the higher the likelihood of successful transplant. This 
hypothesis makes intuitive sense from a statistical standpoint. However if this were the 
entire explanation for differential take rates, transplantation of larger fragments of lower 
grade tumors should address the problem of low take rates because more TIC would be 
present in the transplant. Given the widespread failure of several investigators to establish 
lower grade tumors under a variety of conditions, this explanation, while plausible, is not 
likely to account entirely for the elevated take rate in high grade cancers.
One other plausible explanation for differential take rates of low grade (including DCIS) 
versus high grade cancers is that immunocompromised mouse hosts do not express one or 
more factors that low grade tumors require for growth in mice - factors that at least some 
higher grade tumors do not require (analogous to a shift from hormone-dependent to 
hormone-independent tumor growth in some ER+ breast cancers).
In addition to this potential contribution of tumor evolution/progression, there are several 
known incompatibilities between human and mouse ligand/receptor pairs that may interfere 
with the ability to transplant human tumors into mice efficiently. For example, several mouse 
ligands (e.g. prolactin, hepatocyte growth factor (HGF), interleukin-6 (IL-6)) do not activate 
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their human receptor counterparts [174–176]. Thus, tissue-appropriate expression of one or 
more of these human ligands either as transgenes, or as knock-in constructs, in an 
immunocompromised mouse background may be necessary to stimulate growth of lower 
grade tumors.
One technical modification that may help with growth of lower grade tumors is the use of 
Matrigel or similar basement membrane extract preparation in the transplantation process. 
Head-to-head comparisons of take rates with and without Matrigel using otherwise identical 
host mice and tissue sources have not been conducted. That said, a comparatively high take 
rate of 37% (10 of 27 patients) was achieved [69] using primary tumor fragments or 
metastatic cells (pleural fluid/ascites) coated in Matrigel and implanted into the intact fat pad 
of either estradiol supplemented NOD/SCID or NSG mice. However, this reported take rate 
appears to have been attenuated with additional patient samples attempted (Table 3). There 
also may be some indication that the use of Matrigel in the context of the IFP may help 
somewhat (Table 3). However, using previously cryopreserved tissue, the addition of 
Matrigel under otherwise identical transplant conditions does not appear to enhance the take 
rate (Table 3).
Another promising approach is the use of intraductal injection of cells. This method has 
been used to grow DCIS [153], ER+ and HER2+ breast cancer [154] and molecular apocrine 
cancers [141], with excellent recapitulation of the biology of the source tissue. The 
intraductal approach may allow human epithelium to interact with normal epithelium in 
much the same way that it would in a patient, thereby perhaps allowing growth whereas 
isolated fragments of human tissue may not grow in the absence of such interactions.
III.H.1. Progress toward development of mouse models of human breast 
premalignant lesions—For a comprehensive review of human DCIS models including in 
vitro models, please refer to Kaur, H et al. [177].
Efforts toward developing models of premalignant breast lesions go back to 1975 when 
Outzen and Custer reported transplantation of small fragments of human “cystic 
hyperplasias” into cleared mammary fat pads of nude mice and the lesions were maintained 
for 2–3 months [178]. The hyperplastic lesions proliferated in mice and recapitulated the 
histologic patterns of the original patient biopsy specimens [60]. Other investigators also 
reported that fragments from human breast atypical hyperplasias could be maintained for up 
to ~ 6 months in nude mice and sometimes, the lesions would dedifferentiate meaning that 
they potentially progressed by forming disorganized epithelial hyerplasias. Three 
transplantation sites were used, cleared mammary fat pad, subcutaneous and intraperitoneal. 
The cleared mammary fat pad site was reported to result in the highest take rate (reviewed in 
[178]). Later a study in 1997 reported transplantation of fragments from 25 cases of human 
ductal carcinoma in situ (DCIS) in the back of athymic nude mice [179]. Fragments were 
recovered 2–8 weeks after transplantation and maintained their DCIS components in 93% of 
transplants [179]. The purpose of this study was to analyze ER expression in the 
transplanted DCIS and to assess their response to estrogen supplementation. However, the 
authors reported no expansion in response to hormonal supplementation during the 8 week 
follow up. In a more recent study, human DCIS tissue fragments were implanted 
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subcutaneously in athymic nude mice in order to study the therapeutic efficacy of a farnesyl 
transferase inhibitor. The DCIS xenografts were maintained for up to 21 days and showed a 
take rate of about 66% [180]. Recently, Espina V, et al., demonstrated successful 
xenotransplantation of freshly procured DCIS organoids and in vitro propagated spheroids 
derived from patient DCIS biopsy or surgical specimens. This group reported that tumors 
formed in mice at a rate of ~80% (21/27 cases transplanted) from both freshly procured 
organoids from DCIS of any grade or propagated DCIS organoids passaged in vitro for 2–12 
months.
Towards the development of cell lines that would mimic the histologic and molecular 
features of premalignant breast lesions in xenografts, Miller, FR and colleagues developed 
MCF10AT cell line models. Xenografted lesions derived from MCF10AT cells generated the 
full spectrum of human breast lesions including normal ducts, hyperplasia, atypical 
hyperplasia, carcinoma in situ and invasive cancers [181,182]. A clonal derivative of a 
tumorigenic variant of MCF10AT xenografts, MCF10DCIS.com, produced comedo DCIS 
when transplanted at early passages into cleared fat pads of immunodeficient mice. 
Subcutaneous injection of MCF10DCIS.com into nude mice resulted in rapidly growing 
lesions that were predominantly comedo (a more-aggressive type of DCIS with central 
necrosis) [178]. When transplanted subcutaneously, the MCF10DCIS.com lesions appeared 
in about 3 weeks and were composed of luminal epithelial cells surrounded by both a 
myoepithelial cell layer and a basement membrane. Some areas of early lesions progressed 
to invasive cancers in about 5 to 6 weeks [183]. Another premalignant cell line model 
SUM225CWN was derived from a chest wall recurrence of a ductal carcinoma lesion [184]. 
Similar to those of MCF10DCIS.com, xenografts of the SUM225CWN cell line form DCIS-
like lesions in NOD-SCID mice in as early as 2 weeks [185].
With the idea that human DCIS initiates inside the ducts, Behbod, F et al., utilized the 
intraductal transplantation technique [153]. This approach, referred to as mouse-intraductal 
(MIND) involves injection of epithelial cells derived from DCIS patient samples or cell lines 
directly into the immunocompromised mouse mammary ducts. This is the first model to 
capture the natural evolution of human DCIS in mice since, similar to humans, the cancer 
cells initially form in situ lesions inside the mammary ducts followed by invasion as they 
bypass the natural barriers of ductal myoepithelial cell layer and basement membrane. 
Initially, MCF10DCIS.com and SUM225CWN cells as well as one case of primary human 
DCIS were utilized. The DCIS-like lesions generated from the MCF10DCIS.com 
(DCIS.com) and SUM225CWN cell lines formed DCIS-like lesions as early as two weeks 
and slowly progressed to invasive lesions in 10–14 weeks [153]. Later, in 2011, this group 
reported reproducible growth and expansion of epithelial cells derived from patient DCIS 
biopsy and/or surgical samples as well as hyperplasias in NOD-SCID IL2rg mice by the 
MIND method. The xenografted DCIS like lesions and hyperplasias expressed similar 
biomarkers (ER, PR and Her-2) as the original patient samples. The DCIS like lesions 
generated by the primary DCIS cells in MIND models formed in situ lesions as early as 8 
weeks and a fraction of those slowly progressed to invasive lesions in 6–12 months 
following transplantation (Behbod, F unpublished results). The take rate for primary DCIS 
MIND models is ~50%. A key difference of the MIND method is that pure epithelial cells 
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are injected intraductally as opposed to previous methods that transplanted organoids or 
pieces of tissues in the cleared mammary fat pads of immunocompromised mice.
III.I. Can “Humanization” of Immunocompromised Mice Enhance Take Rate and Improve 
Translational Relevance?
There are currently two different classes of “humanization” methods that are being explored 
for their ability to enhance PDX growth, and perhaps provide a more biologically similar 
environment as in the tumor of origin.
III.I.1 “Humanization” of the mammary fat pad—A few groups have attempted to 
increase the efficiency of primary tissue transplantation by “humanizing” the mammary fat 
pad of mice with the introduction of an immortalized human fibroblast cell line into the 
mammary fat pad prior to xenograft transplantation [75,87,186]. Use of this methodology 
allowed organotypic growth of normal human mammary epithelium, and appears to allow 
PDX establishment under some circumstances (Table 3). However, Zhang et al [54] showed 
that provision of immortalized fibroblasts attenuated take rates considerably using 
statistically comparable cohorts in the SCID/Bg background reducing the rate from 21.4% to 
3.4% under otherwise identical transplantation conditions. Thus, it remains unclear whether 
immortalized fibroblasts enhance PDX take rates.
Aside from immortalized fibroblasts, it is also possible that co-transplantation of 
mesenchymal stem cells may enhance PDX take rates. These cells were shown to enhance 
mammosphere formation in vitro [187,188], and to stimulate growth and metastasis of 
established xenografts in vivo [71,189,190,175]. However, this approach has not yet been 
tested extensively.
III.I.2. “Humanization” by reconstitution of the human immune system in 
immunocompromised mice—A disadvantage of any xenograft as a model for human 
cancer is growth of the tumors in immunocompromised mice, which is required in order to 
avoid rejection of the tumor by the host mouse immune system. Lack of normal immunity in 
tumor xenografts is an important caveat, given the well-established, multiple roles of the 
immune system in tumor initiation and growth, metastasis, and response to therapy. In most 
patients, tumors arise in the presence of a functional immune system, and the tumor evolves 
to evade immune rejection under selective pressure [191]. Once a tumor is detectable it has 
already avoided immune-mediated rejection, and thereafter, the immune system actually 
plays a paradoxical role in promoting tumor progression and metastasis [192–194]. For 
example, macrophages can assist with tumor cell intravasation to facilitate tumor 
dissemination [195]. Myeloid-derived suppressor cells can promote angiogenesis and 
suppress adaptive immune responses [196], and regulatory T cells reinforce the 
immunosuppressive tumor microenvironment [197].
On the other hand, it has been clear for a number of years that the immune system can, in 
some cases, be successfully stimulated to eradicate tumors. Indeed, recent advances in 
immunotherapy using immune checkpoint inhibitors have led to exciting therapeutic results 
in certain cancers [198,199]. The immune system is also instrumental in sustaining tumor 
regression upon oncogene inactivation [200], which is highly relevant when considering 
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therapeutic effects. Therefore, incorporation of a functional or partially functional human 
immune system into xenograft models might more accurately model human breast cancer 
growth, metastasis, and response to therapy, particularly those known to involve an immune 
system function in their mechanism of action.
Generation of mice with reconstituted human immune systems was first accomplished in 
1988 [201], and is now commonly used to study human blood cell development and diseases 
of the hematopoietic system [65]. The idea of using mice with ‘humanized’ immune systems 
to study human cancer is not new, but until recently has been mostly focused on tumors of 
the hematopoietic lineage. Immune humanization in mice carrying human breast cancers is 
now feasible [202], with two key stipulations: (1) the mouse host has to be appropriate for 
growth and development of human tumor cells and human immune cells; and (2) the 
immune system must not recognize the tumor as foreign and reject it (graft vs. tumor 
reaction). State-of-the-art strategies, as well as caveats, have been recently reviewed 
elsewhere [203–206].
In summary, it has become clear that the “tumor cell-centric” approach to breast cancer 
therapy may not be sufficient to eradicate the disease, and a dual approach targeting both the 
tumor and its specialized microenvironment might be more effective [207]. Many promising 
therapies for breast cancer rely on an effective anti-tumor immune response, and they need 
to be tested pre-clinically in animal models before entering trials. Examples include vaccines 
for breast cancer prevention or inhibiting outgrowth of occult metastasis [208]; drugs to 
prevent macrophage recruitment into tumors where they promote metastasis [209]; or new 
immune checkpoint inhibitor combinations [210]. In all cases, a better understanding of 
human tumor-immune interactions is needed. Future development of PDX models in mice 
with matched, functioning human immune systems may hold potential to advance breast 
cancer research and lead to new treatments.
III.J. What do we need to do to make PDX repositories truly clinically relevant? Toward 
development of data standards for “clinical” annotation of patient breast cancer samples 
and their associated PDX models
As a newly formed international consortium, we herein report details of a large collection of 
breast cancer PDX models that recapitulate patient biology to a high degree. However, the 
patient-related clinical data, and PDX-related data collected by each individual group varies 
significantly, both in terms of content and terminology used. This review therefore provides 
an opportunity to begin a discussion about development of an international data standard that 
can be adopted by all PDX generating groups to allow direct comparison of collections 
worldwide, and provide the foundation for larger-scale international, multi-institutional 
collaborations. Ideally, data elements used should integrate well with existing data 
repositories and portals such as GEO, Oncomine, and cBioPortal etc. by having a shared 
conceptual understanding and similar terminology that allows direct mapping of data 
elements between PDX resources and data portals. Significant progress has been made in 
this area, including community discussions about standards for data format and content that 
will enhance data sharing and integration, which will be discussed in detail at a later date.
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There are two broad classes of data that can be collected: clinical data about the patient and 
tumor of origin, and PDX-centric data about the characteristics of the xenografts themselves. 
Within these two broad classes, the amount of data that can potentially be collected is 
relatively large, while the ability to collect detailed data may be limited by personnel 
availability and financial support. In particular, with patient privacy laws in effect in various 
countries, care must be taken to firewall personally identifiable health information from 
other data that can be shared publicly without concern that privacy will be compromised. To 
accomplish this division requires dedicated “clinical” personnel with clearance to access and 
abstract clinical data, and an independent group of dedicated “PDX” personnel with access 
to the abstracted clinical data, as well as PDX-based data elements and datasets. Finally, 
both of these efforts require significant involvement of bioinformatics and software 
development expertise for proper integration.
Clinical data can be collected with varying degrees of ease, and can be divided into what 
might be considered a “minimal”, or “essential” data set, and a more expanded “ideal” data 
set at both the patient level and the sample level. At the patient level, it is essential that one 
knows the gender of the donor, the clinical event point that defines the sample type(s) that 
have been collected from the patient for use in PDX generation (e.g. Benign/Normal, 
Primary tumor, Second Primary Tumor, Local Regional Recurrence, Distant Metastasis, 
Unknown) and pathological stage (including nodal status etc).
In addition to these minimal data, there are several other data elements that greatly increase 
the utility of a renewable tissue resource for use in translational studies and drug evaluation. 
These include, patient age at each clinical event point (e.g. biopsy, surgery at which time the 
sample used for generating a PDX was taken), parity history, race, ethnicity, family history 
of cancers, vital status and date of recording, and any sites of distant metastasis. These data 
would ideally also include treatments received by the patient, the timing of treatment relative 
to the time of tissue collection for the production of PDX models, and the treatment 
response of the tumor of origin (most easily evaluated in the neoadjuvant setting).
At the sample level, minimal data include pathological diagnosis of the sample taken, 
hormone receptor status (ER/PR) and percentage of positivity, HER2 status, and germline 
BRCA1/2 mutation status of the tumor of origin for the resulting PDX lines to be maximally 
useful. Additional data of interest related to the sample used for PDX generation include 
Ki67 labeling index, status of commonly mutated genes like TP53 and PIK3CA, pathologic 
stage and grade, molecular subtype (by multiple means), and treatment status at the time of 
collection. Short tandem repeat (STR) analysis is also essential, whenever possible, to 
ensure accurate patient/PDX relationships. Given the recent reports of selective outgrowth of 
Epstein-Barr virus-positive human lymphomas in attempts to generate solid tumor PDX 
models [143,144], it is imperative that each PDX model be validated appropriately with 
cytokeratin and CD45 immunohistochemical staining.
Because the PDX itself is a renewable sample type, tissue is not limiting. Thus, the PDX can 
be characterized to a high degree without concern of exhausting the tissue, although 
maintaining low passage lines is a clear priority. Key PDX-based data types are essentially 
identical with sample-level data types collected clinically. Namely, it is critical to confirm 
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ER/PR/HER2 status in the PDX at different passages, and to conduct STR analysis to 
establish the unique identity of the PDX line and to establish the direct patient/PDX 
relationship whenever possible, and for downstream quality control measures to ensure PDX 
identity and integrity over what are likely to be decades of passage in the future.
In addition to these minimal data, other data that are useful are PDX growth rates (doubling 
time), metastatic frequency (CTC, lung, liver, bone, lymph node, brain etc.), and any number 
of “-omics” characterizations. The “-omics” characterizations possible to generate include, 
but are not limited to, genomic copy number alterations, mutation status in various genes 
(whole genome sequencing, exome sequencing, Sequenom, SNP analysis etc.), methylome, 
gene expression at both the RNA level (RNAseq, Array-based, QPCR etc.) and protein 
levels (Reverse phase protein array, mass spectrometry, Western blot, CyTOF), metabolome 
(mass spectrometry-based), among other possibilities. All data can then be correlated to any 
subsequent behavior or response that a given PDX, or set of PDX models, may have to 
experimental manipulation. Such correlations should be particularly important for evaluation 
of drug treatment responses (any number of agents, but specifically standard of care agents). 
To be particularly powerful, PDX-based –omics characterizations should be matched to the 
corresponding data derived from the tumor of origin whenever possible. However, given that 
patient samples are typically limited by size, this is not always possible.
IV. Summary of Strengths and Limitations of PDX Models For Translational 
Research and Drug Development
PDX models are potentially important tools for identifying mechanisms of de novo and 
acquired drug resistance, for identifying new biomarkers of breast cancer biology, for 
driving drug discovery, and for evaluation of new experimental therapeutics. Although 
superior to cell lines in recapitulating tumor heterogeneity, PDX models are also biased 
towards more aggressive tumors and the rate of engraftment can be an independent predictor 
of patient outcome. While the majority of PDX models represent TNBC, there has been 
substantial improvement in establishing HER2+ and ER+ luminal B tumors. As predicted, 
more differentiated ER+ tumors with a low Ki67 staining index are very difficult to engraft, 
and in cases where they do engraft, it is likely that selection for the most undifferentiated 
components of the tumor has occurred, resulting in a tumor quite different from that in the 
original patient. Thus, rates of engraftment are skewed towards the most undifferentiated 
subtypes of breast cancer and do not fully encompass inter-tumor heterogeneity.
The recent findings that the clonal dynamics of tumors are highly variable, ranging from 
minor changes on engraftment to extensive changes that accompany selection for a minor 
clone of originating cells, adds a further degree of complexity [44]. Nevertheless, 
polyclonality is generally well-represented by breast xenografts, and they continue to serve 
as useful models provided their clonal repertoire is taken into consideration. Although 
metastatic lesions demonstrate improved take rates and growth, they cannot be used to study 
the process of metastasis from naïve tumors.
One of the major limitations of the PDX model is the deficiency of the mouse host immune 
system and selectively inappropriate microenvironmental influences. Severely 
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immunodeficient hosts must necessarily be utilized but these inevitably alter the growth 
kinetics of many PDX tumors and preclude evaluation of immune-modulatory therapies. The 
NSG mice is currently the most widely used strain, but these lack natural killer cells, B and 
T lymphoid cells. Humanization of the immune system could in theory be achieved by 
mobilizing peripheral blood stem cells from the same patient, although this remains 
challenging on more than one front. Other options include humanization of the mouse 
immune system by co-engraftment of human bone marrow cells [211].
In addition to immune system deficiency, PDX models lack human stromal components 
such as the different fibroblast populations, endothelial cells and adipocytes, being replaced 
by their mouse counterparts which do not function identically. The growth factors and 
stromal requirements necessary for effective engraftment are poorly understood and human 
fibroblasts are rapidly out-competed by mouse stromal cells following transplantation [71]. 
Genetic targeting of multiple human cytokine genes into their respective loci within mice 
[212] might improve tumor engraftment through the provision of crucial stroma-derived 
species-specific cytokines. In addition, one might expect that co-engraftment of 
mesenchymal stem cells or cancer-associated fibroblasts could enhance tumor growth and 
stabilize tumor heterogeniety. Despite these ideas, the key to fully efficient tumor 
engraftment is not still known.
PDX models have been shown to recapitulate the drug sensitivity responses observed in the 
tumors of patients, from which they were derived. However, the implementation of PDX 
mice as ‘Avatar models’ to guide clinical decisions will require significant advances in this 
area, including rigorous comparison of pharmacokinetic and pharmacodynamics for various 
agents that will allow “preclinical trials” in PDX-bearing mice to be as comparable as 
possible to clinical trials as conducted with patients. Aside from the limitations owing to 
lack of a human immune or stromal system, one of the limiting issues is the time-scale 
required to establish PDX models for drug testing. We also need to collect data about 
adverse drug reactions in different mouse strains. Furthermore, not all patient tumors 
engraft, adding a level of unpredictability. In order for PDXs to be relevant to the individual 
patient, the engraftment rate and time required for engraftment need to be dramatically 
optimized and standardized, without compromising the biological properties of the original 
patient tumor.
At this stage in their credentialing, PDX models best serve as basic and translational 
research tools, where they can have considerable impact. One of the best examples has been 
seen in the case of colorectal cancer, where PDX studies showed that tumors with a mutated 
KRAS gene were not responsive to cetuximab [213], closely mimicking that seen in large 
clinical trials. These results provide compelling support for PDX models as predictors of 
clinical response and their further implementation could circumvent long-term, costly 
clinical trials in the future [214].
V. Focus for the future
At some point, perhaps even very soon, the more aggressive forms of breast cancer will be 
represented well enough in the PDX community that it is no longer necessary to expend 
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additional resources and effort to develop new PDX lines to represent them. Rather, it may 
be more fruitful to redirect resources to generate PDX lines for underrepresented tumor 
types or patient populations. These underrepresented tumor types and populations may offer 
insights into breast disease that would not be found otherwise, and would likely facilitate 
development of personalized medicine strategies.
It has already been mentioned that ER+ Luminal A and HER2+ tumors, grade I/II tumors, 
DCIS, and hyperplasias are significantly underrepresented in the PDX collections reported 
herein, but the increased use of the intraductal approach may remedy this situation. 
Similarly, there are very few claudin-low or metaplastic tumors present in the current 
collection; these are tumors with very poor prognosis and limited treatment options. As 
such, focused effort to establish PDX models representing these underrepresented tumor 
types may be preferable to the broader efforts currently underway.
In addition to these more familiar tumor types, there are other classes of tumors that are also 
underrepresented, on which focused attention might be warranted. For example, while some 
models do exist, tumors from Hispanic, African American, Asian, and Native American, and 
other indigenous peoples, are still underrepresented. Similarly, while males do develop 
breast cancers, there are presently no male breast cancers represented in the PDX collections 
presented herein. Finally, if the proper infrastructure were developed, we have the 
opportunity to try to generate PDX models from areas of the world in which health care is 
limited, and PDX generation efforts are entirely lacking. Together, these rare and 
underrepresented PDX models may provide unexpected insights that cannot be foreseen.
Conclusions
1. PDX models representing clinically-relevant subtypes of breast cancer are 
available as phenotypically stable, renewable tissue lines.
2. Breast cancer PDX recapitulate many key aspects of the biology of the tumor of 
origin and therefore may serve as excellent models for translational research.
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1. To what extent can PDX models be used as patient “avatars” in preclinical 
evaluation of experimental therapeutics?
2. Can PDX-based “-omics” studies be used to develop predictive signatures and 
to identify key resistance mechanisms?
3. Under what circumstances does the lack of an intact immune system 
influence the usefulness of PDX models, and can this be overcome?
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Table 2
Contact Information for PDX Collections
Academic Institution Contact Name and E-mail
Baylor College of Medicine (USA) Michael Lewis (mtlewis@bcm.edu)Lacey Dobrolecki (dobrolec@bcm.edu)
Bellvitge Institute for Biomedical Research (SPAIN) Eva Gonzalez-Suarez (egsuarez@idibell.cat)
British Columbia Cancer Agency (CANADA) Samuel Aparicio (saparicio@bccrc.ca)
Ecole Polytechnique Federale De Lausanne (CH) Cathrin Brisken (cathrin.brisken@epfl.ch)
Institut Bergonié (FR) Richard Iggo (r.iggo@bordeaux.unicancer.fr)
Institut Curie (FR) Elisabetta Marangoni (elisabetta.marangoni@curie.fr)
The Jackson Laboratory (JAX) (USA) Carol Bult (Carol.Bult@jax.org)Susie Airhart (Susie.Airhart@jax.org)
MD Anderson Cancer Center (USA) -Meric-Bernstam Funda Meric-Bernstam (fmeric@mdanderson.org)
MD Anderson Cancer Center (USA) -Piwnica-Worms Helen Piwnica-Worms (hpiwnica-worms@mdanderson.org)
University of Colorado Anschutz Medical Campus (USA) Carol Sartorius (Carol.Sartorius@ucdenver.edu)Peter Kabos (Peter.Kabos@ucdenver.edu)
University of Manchester Institute of Cancer Sciences (UK) Robert Clarke (Robert.Clarke@manchester.ac.uk)Denes Alferez (denis.alferez@manchester.ac.uk)
University of Michigan (USA) Max Wicha (mwicha@med.umich.edu)
University of Utah -Huntsman Cancer Institute (USA) Alana Welm (Alana.Welm@hci.utah.edu)
Walter and Eliza Hall Institute of Medical Research (WEHI) (AU) Geoffrey Lindeman (lindeman@wehi.edu.au)Jane Visvader (visvader@wehi.edu.au)
Washington University (USA) Shunqiang Li (shunqiangli@wustl.edu)
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Table 4




Abbreviation Full Strain Designation Vendor
Stock
Number































Ecole Polytechnique Federale De
Lausanne (SW)
NSG NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ JAX 005557
Institut Bergonié (FR) NSG NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ JAX; bred in house 005557
Institut Curie (FR) Swiss Nude Crl:NU(Ico)-Foxn1nu CR
The Jackson Laboratory (JAX) (USA) NSG NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ JAX 005557
MD Anderson Cancer Center (USA)
- Meric Bernstam
Nude Athymic Nude - Foxn1nu MDACC Colony NA
MD Anderson Cancer Center (USA)
- Piwnica-Worms
NOD/SCID NOD.CB17-Prkdcscid/NcrCrl CR 394







JAX; bred in house
001303
005557
University of Manchester Institute
of Cancer Sciences (UK) NSG NOD.Cg-Prkdc
scid Il2rgtm1WjI/SzJ JAX via CR 005557




JAX; bred in house 005557;
001303
University of Utah Huntsman -
Cancer Institute (USA)
NOD/SCID NOD.CB17-Prkdcscid/J JAX 001303
Walter and Eliza Hall Institute of
Medical Research (WEHI) (AU)
NSG NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ JAX; bred in house 005557
Washington University (USA) NSG NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ JAX 005557
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